The human ether-a-go-go-related gene potassium channel (hERG, Kv11.1, KCNH2) has an essential role in cardiac action potential repolarization. Electrical dysfunction of the voltage-sensitive ion channel is associated with potentially lethal ventricular arrhythmias in humans. hERG K þ channels are also expressed in a variety of cancer cells where they control cell proliferation and apoptosis. In this review, we discuss molecular mechanisms of hERG-associated cell cycle regulation and cell death. In addition, the significance of hERG K þ channels as future drug target in anticancer therapy is highlighted. Cell Death and Disease (2011) 2, e193; doi:10.1038/cddis.2011.77; published online 18 August 2011
Subject Category: Cancer
Ion Channels Involved in Cell Proliferation and Death
Ion channels have been implicated in signaling pathways leading to cell proliferation or apoptosis (programmed cell death). Their identification and functional characterization in tumor cells suggest potential significance in anticancer therapy. Transient receptor potential channels form a superfamily of ubiquitously expressed channels influencing the balance between cell survival and death. 1, 2 In addition, hyperpolarization-activated cyclic nucleotide-gated channels were detected in embryonic stem cells where they exert proproliferatory effects. Potassium channels represent the largest group of channels involved in cell death and proliferation. 3, 4 Calcium-activated K Ca 3.1 channels contribute to proliferation and atherosclerosis, and inhibition of the current attenuates fibrosis and lymphocyte proliferation. [5] [6] [7] [8] Furthermore, voltage-gated K þ channels (e.g. Kv1.
3) or twopore-domain channels (e.g. K 2P 5.1) determine growth of adenocarcinomas. 9, 10 Voltage-sensitive human ether-ago-go-related gene (hERG) potassium channels have recently emerged as novel regulators of growth and death in cancer cells. This review focuses on hERG channels in proliferation and apoptosis. Current knowledge on expression, function and regulation is reviewed, and clinical implications are discussed.
Differential Expression of hERG Potassium Channels
Cardiac expression and function of hERG K þ channels. Repolarization of cardiac ventricular myocytes is mainly regulated by outward potassium currents. One of the most important currents is the delayed rectifier potassium current, I K , which has rapidly and slowly activating components (I Kr and I Ks ). 11 Activation of the rapid component of the delayed rectifier potassium current, I Kr , terminates the plateau phase and initiates repolarization of the cardiac action potential. The hERG encodes the voltage-gated potassium channel a-subunit underlying I Kr .
12-14 hERG potassium channels form homo-tetramers of identical six transmembrane spanning domains, with a cluster of positive charges localized in the S4 domain serving as voltage sensor. hERG channels are a primary target for the pharmacological management of arrhythmias with class III antiarrhythmic agents. 15, 16 Blockade of hERG currents causes lengthening of the cardiac action potential, which may produce a beneficial class III antiarrhythmic effect. Excessive reduction of HERG currents due to mutations in hERG or via blockade produces chromosome-7-linked congenital long QT syndrome (LQTS-2) and acquired long QT syndrome, respectively. Both forms of LQTS are associated with delayed cardiac repolarization, prolonged electrocardiographic QT intervals, and a risk for the development of ventricular 'torsade de pointes' arrhythmias and sudden cardiac death. hERG channels are inhibited by a variety of non-antiarrhythmic compounds. This undesirable side effect is now considered a significant hurdle in the development of new and safer drugs, and has forced removal of several drugs from the market. In addition to LQTS, cardiomyocyte apoptosis has been reported following pharmacological hERG K þ channel blockade. 17 hERG K þ channels in cancer. Various cancer cell lines of epithelial, neuronal, leukemic, and connective tissue origin express hERG K þ channels (Table 1) , whereas corresponding non-cancerous cells and cell lines do not 21, 22 In addition, increased neoangiogenesis, another hallmark of malignant tissue growth, has been reported for glioblastoma where the generation of blood vessels was stimulated by hERG-dependent secretion of vascular endothelial growth factor. 27 Differential hERG expression patterns during ontogenesis. While hERG expression in normal adult human tissue is limited to heart, brain, myometrium, pancreas, and hematopoietic progenitors, other species have been described to undergo changes in their ERG expression profile during ontogenesis: quail embryos express ERG K þ channels in peripheral ganglia and skeletal muscle in addition to heart and central nervous system. 47 This observation illustrates that hERG expression in tumor cells might either represent ectopic re-expression of a gene that remains silent in differentiated cells, or reflect reactivation of embryonic genes, which is well recognized in cancers. 35 
Cell Proliferation
Functional role of hERG K þ channels in cell proliferation. In differentiated adult cells, resting membrane potential varies from À40 mV to about À90 mV. 48 These distinct differences are closely correlated to the proliferative potential of respective cell types, ranging from slowly proliferating or non-proliferative neurons or muscle cells (À70 mV to À90 mV) to highly proliferative glandular epithelia of liver, thyroid, pancreas, or salivary glands (À40 mV to À55 mV). 48 hERG K þ channels are closed at membrane potentials below a threshold of BÀ60 mV 1 whereas classical inwardly rectifying channels remain open at more negative membrane potentials. 49 The predominance of hERG in cycling cells may thus account for the depolarized resting membrane potential in these cells. 31 The membrane potential of cycling cells is particularly depolarized during the G1 phase. However, K þ channel-dependent hyperpolarization appears to be critical for progression to the S phase. Hyperpolarization evokes Ca 2 þ influx, which is further augmented by calciumdependent K þ (K Ca ) channels and permits synthesis of mitogenic factors. In addition, hyperpolarization provides the electrical gradient necessary for Na þ -dependent transport of metabolic substrates and ions across the plasma membrane, which is required for DNA synthesis. 50 Considering that K þ channels are involved in cell cycle progression, abundant expression of K þ channels is expected to cause loss of proliferative control if endogenous pathways fail to block excessively expressed K þ channels. 50 Interestingly, the promoter region of the hERG gene harbors multiple binding sites for oncoproteins, such as specificity protein 1 and nuclear factor kappa light chain enhancer of activated B-cells, and for the tumor suppressor protein Nkx3.1 (Nk3 homeobox 1). 30 We may hypothesize that mutations in oncoproteins constitutively activate hERG gene expression, shifting resting membrane potentials of cancerous cells toward more depolarized values and repolarizing them at the end of G1 phase, thereby facilitating cell cycle progression and thus leading to cell proliferation. Here, pharmacological intervention using hERG antagonists will serve to arrest the cell cycle in the G1 phase. Furthermore, human gastric cancer cells exhibit reduced levels of the regulatory b-subunit KCNE2, leading to hERG current increase. 51, 52 In addition, genetic deletion of KCNE2 is associated with gastric neoplasia and increased nuclear cyclin D1 levels in mice, revealing genetic manipulation of cell proliferation mediated by a hERG b-subunit.
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Various cancer cell lines and cardiomyocytes have been reported to express an N terminally truncated splice variant of hERG, hERG1b, that confers specific electrophysiological properties. 53 Pharmacological approaches targeting the hERG1/hERG1b ratio may modulate the resting membrane potential of cycling cells. Increased hERG1b levels are expected to depolarize cells, while high hERG1 levels will shift membrane potential toward more hyperpolarized values 35 and suppress cell proliferation.
hERG potassium channel blockers modulate proliferation. Leukemic cell lines express hERG K þ channels whereas noncancerous lymphocytes do not exhibit hERG protein. Selective hERG channel blockade by E-4031 reduced proliferation in cancerous cell lines. 25 Unspecific deceleration of the cell cycle and reduction of cell proliferation 50 were ruled out in Furthermore, additional structurally different hERG blockers have been shown to achieve cell cycle arrest in G1 phase of hERG-positive cells (Table 2 ). It is noteworthy that the hERG blocker erythromycin blocks cell cycle in G2 phase if administered together with vincristine. 29 In addition, hERG blockers doxazosin and terazosin did not cause cell cycle arrest despite hERG expression in distinct cell lines, for example, LNCaP prostate carcinoma cells.
30,57
Significance of hERG Ion Channels in Apoptosis Proapoptotic effects of hERG K þ channel inhibitors. hERG channel blockers have been shown to induce apoptosis in different cell types. This mechanism is independent of their capacity to inhibit cell proliferation via cell cycle arrest. The significance of hERG K þ channels in apoptotic pathways has been demonstrated in hERGtransfected HEK293 cells, which underwent apoptosis upon administration of doxazosin, compared with control HEK293 cells lacking endogenous hERG. 58 Doxazosin is an a 1 -adrenocepor antagonist with hERG-blocking properties that is clinically used as antihypertensive drug. 59 In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which compared novel antihypertensive drugs to diuretic treatment in 33 000 patients, the doxazosin arm had to be discontinued due to an increase in congestive heart failure that may be attributed to cardiomyocyte apoptosis. 60, 61 The proapoptotic effect of doxazosin has been confirmed in vitro in the murine atrial tumor cell line HL-1 and in isolated adult human cardiomyocytes, 17 providing a possible explanation for the increased incidence of congestive heart failure in the doxazosin arm of the ALLHAT trial. In addition to hypertension, doxazosin is used for treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH). Smooth muscle relaxation due to a 1 -adrenergic blockade was initially thought to underlie the relief of symptoms in BPH patients. However, subsequent studies revealed an apoptotic effect of doxazosin in hyperplastic prostatic tissue that may contribute to its clinical efficacy. 62 Furthermore, doxazosin induced apoptosis in prostatic cancer cells. 63 Limitations arise from the lack of studies directly comparing hERG expression in normal, hyperplastic, and cancerous prostatic tissue, respectively. Finally, hERG channel expression is well documented in pituitary adenoma cells. 45 When treated with doxazosin in vitro, antiproliferative and proapoptotic effects were observed in pituitary adenoma cells independent of antiadrenergic properties of the drug. 55 Molecular mechanisms of hERG-associated apoptosis. hERG K þ channel blockers such as doxazosin activate multiple apoptotic pathways. However, evidence for a direct mechanistic link between hERG K þ channels and apoptotic proteins remains sparse to date. In HL-1 cardiomyocytes, doxazosin induces apoptosis via the endoplasmic reticulum pathway, involving enhanced phosphorylation of p38 mitogen-activated protein kinase, which activates GADD153/CHOP (growth arrest and DNA damage-induced gene 153/c/EBP homologous protein). GADD153/CHOP subsequently forms heterodimers with DNA-binding protein c/EBPb (CCAAT enhancer-binding protein beta) and translocates into the nucleus, where it augments transcription of the carbonic anhydrase DOC-1 (downstream of CHOP-1). DOC-1 then acidifies intracellular pH and facilitates apoptosis. 64 Finally, the CHOP pathway results in activation of a key apoptotic enzyme, caspase 3. 65 Caspase activation by doxazosin induces cleavage of the protein-tyrosine kinase FAK (focal adhesion kinase) in HL-1 cells, which compromises cell adhesion and leads to apoptosis. 64 FAK is an essential component of integrin signaling and is phosphorylated when cells are adhered to the extracellular matrix. Thus, it provides a survival signal and prevents apoptosis. 66 In prostate cancer cells, FAK is cleaved by caspase 3 upon treatment with doxazosin, which leads to apoptosis or anoikis (i.e. apoptosis due to loss of cell adhesion). 67 Furthermore, hERG1, integrin b1, and FAK form a macromolecular complex in hERG1-transfected HEK293 cells and SH-SY5Y neuroblastoma cells. Cell adhesion via integrin b1 causes activation of hERG1, which is essential for direct FAK phosphorylation (Figure 1) . 37 FAK and hERG overexpression have independently been related to enhanced dissemination and invasiveness of tumors. 20, 66 FAK phosphorylation due to hERG activation may explain the ability of malignant cells to circumvent apoptosis once they have lost contact to the extracellular 55 
Doxazosin
Arrest in G1 phase Rat somatolactotroph GH3 cells 55 
Arrest in G1 phase MCF-7 breast cancer cell line 56 
Astemizole
Arrest Cell type-and environment-specific effects on apoptosis are suggested by reports of hERG activity promoting apoptosis. In hERG-positive SKBr3, SH-SY5Y, and HL-1 cells, apoptosis occurs via a caspase 3-dependent pathway in response to extracellular administration of H 2 O 2 or TNFa (tumor necrosis factor a), whereas selective inhibition of hERG conductance by dofetilide attenuates the proapoptotic effect of H 2 O 2 and TNFa. 33 The methodology in the latter study is different from investigations mentioned above. Cells were first incubated with H 2 O 2 or TNFa to induce apoptosis, followed by application of hERG blockers. In the same study, hERG is revealed to recruit TNFa receptor 1 to the plasma membrane, which might explain increased responsiveness to TNFa in these cells. 33 The authors describe a proliferative effect in hERG-expressing cells at low doses of TNFa and an antiapoptotic effect of the hERG inhibitor dofetilide upon pretreatment with H 2 O 2 and TNFa. These observations appear to be at odds with proapoptotic effects of hERG K þ channel blockers. The hERG blocker doxazosin has been proven as a proapoptotic agent in a wide range of in vitro and in vivo studies. Doxazosin increases the intracellular H 2 O 2 content in BPH stromal cells. This is considered to facilitate TNFa-related pathways. 68 Administration of H 2 O 2 before hERG inhibition appears to interfere with hERG-induced signaling pathways, which augment intracellular H 2 O 2 levels. The antiapoptotic effect of hERG channel blockade may be due to this interference. However, pro-and antiapoptotic effects of hERG blockers might coexist, and proapoptotic effects, including the increase in intracellular H 2 O 2 , could outweigh a possible antiapoptotic effect through suppression of the apoptotic H 2 O 2 -TNFa pathway. However, an unambiguous differentiation between effects of hERG conductance and hERG expression is lacking, and the mechanism by which hERG conductance facilitates H 2 O 2 -and TNFa-mediated apoptosis remains unclear at the molecular level.
Clinical and Therapeutic Implications
Diagnostic value of hERG K þ channel expression in tumors. hERG may be utilized as a potential tumor marker, given their expression in a variety of tumor cells and their absence from most non-cancerous human tissues. Specifically, hERG was detected in endometrial cancer at mRNA (sensitivity ¼ 67%; n ¼ 18) and protein levels (sensitivity ¼ 82%; n ¼ 18), whereas only 18% (n ¼ 11) of non-cancerous endometrial samples exhibited hERG mRNA or protein. 23 In colon carcinomas, hERG mRNA was a more sensitive and more specific indicator for malignancy (100% sensitivity and specificity; n ¼ 23) than mRNA of the established tumor markers CEA (sensitivity ¼ 94.4%; n ¼ 18), CK19 (sensitivity ¼ 77.8%; n ¼ 18), or CK20 (sensitivity ¼ 94.4%; n ¼ 18). 18 Immunohistochemical staining for hERG protein Figure 1 Pathways of hERG-associated apoptosis. Doxazosin induces apoptosis via two independent mechanisms, inhibition of FAK phosphorylation via blockade of hERG K þ channels 37 and caspase 3-mediated cleavage of FAK 67 via induction of ER stress, 64 respectively. In addition, DOC-1 causes a decrease in intracellular pH, which facilitates apoptosis 64 hERG channels in cell proliferation and apoptosis J Jehle et al reached similar sensitivity and specificity as hERG mRNA. 18 Further validation is required in larger patient populations.
Prognostic significance of hERG K þ channel expression in tumors. The prognostic value of hERG expression in tumors has been evaluated in several tissues. In acute myeloid leukemia (AML) blasts, hERG K þ channel expression is associated with a 50% reduction of relapse-free and overall survival time compared with patients with hERG-negative AML (12 versus 23 months) . 69 Patients with esophageal squamous cell carcinomas similarly exhibit reduced survival (30 versus 56 months) when hERG is detected. 22 However, hERG K þ channel expression was not significantly associated with invasiveness, dissemination, or tumor grade in this study. In gastric cancer cells, levels of hERG expression are positively correlated to tumor dedifferentiation and TNM stage. 21 Moreover, tumor growth was observed in BALB/c nu/nu mice following injection of gastric cancer cells. Injection of cancer cells that were pretreated with hERG siRNA significantly attenuated tumorigenesis, 21 confirming the pathological significance of hERG in tumor growth and suggesting a potential novel target in anticancer therapy (see below). In colonic adenocarcinomas, there is a significant correlation between hERG K þ channel expression and invasiveness or dissemination. hERG is not detected in normal colonic mucosa (0%; n ¼ 60) and rarely observed in adenoma (9%; n ¼ 11). In contrast, substantial hERG was found in patients with non-metastatic adenocarcinoma (75%; n ¼ 52) and metastatic adenocarcinoma (100%; n ¼ 8), with the most pronounced staining found in hepatic and peritoneal metastasis. 20 Anticancer therapy. The antihypertensive a 1 -adrenoceptor blocker doxazosin is an established treatment option in BPH. Its therapeutic efficacy has been attributed to induction of apoptosis in hyperplastic and cancerous prostate cells. 57 Furthermore, hERG-positive cancer cells have been reported to be particularly susceptible to chemotherapeutics vincristine, paclitaxel, and hydroxycamptothecin. 29 Direct effects of vincristine, paclitaxel, and hydroxycamptothecin on hERG channels remain to be investigated. Erythromycin, a macrolide antibiotic with hERG-blocking properties, further enhances the antiproliferative effect of these chemotherapeutics. 29 The most intriguing perspective of anticancer therapy targeting hERG channels is direct blockade of the potassium channel, which is expected to produce antiproliferative and proapoptotic effects that diminish tumor growth and invasiveness. The first proof of concept study confirmed prevention of gastric cancer cell proliferation by the hERG K þ channel blocker cisapride. 70 A systematic in vivo investigation of chemotherapeutic properties and potential cardiac side effects of hERG inhibitors is required.
Potential side effects and limitations of anticancer therapy based on hERG current inhibition. Proarrhythmic 14 and cardiotoxic risks of hERG inhibitors require careful evaluation 7 when applying these compounds in clincial oncology. Systemic treatment of cancers with hERG antagonists may affect cardiac myocytes, resulting in apoptosis and heart failure. In addition, application of hERG antagonists may induce QT prolongation and ventricular tachycardia. Although cancer treatment usually occurs in life-threatening situations, and in some cases potential cardiac damage is accepted (e.g. during use of anthracyclines), optimal suppression of these events will be required. To prevent proarrhythmic side effects, short-term drug application may be sufficient to induce apoptosis in tumor cells with minimal effects on cardiac electrophysiology. ECG monitoring should be performed during application of the drug. Additional pharmacological inhibition of cardiac L-type calcium channels or b-adrenoceptors may offset the limiting proarrhythmic effects of hERG channel inhibitors. [71] [72] [73] Cardiomyocyte apoptosis may be circumvented through targeted delivery techniques such as direct injection or trans-arterial drug application. Gene therapy represents an additional therapeutic approach to targeted suppression of hERG channel expression in cancers. Different proliferative states of cardiac and tumor cells may render cancerous tissue more susceptible to proapoptotic and antiproliferative stimuli, reducing the overall risk of heart failure during systemic application of hERG antagonists. Feasibility of tumor-selective hERG-based anticancer therapy will further depend on differential drug effects on cancerous and non-cancerous tissue expressing hERG K þ channels.
Conclusion
hERG potassium channels, previously recognized to promote cardiac action potential repolarization, are now revealed to serve as regulators of proliferation and apoptosis in cancer cells. Their significance in anticancer therapy is supported by mechanistic data and preliminary in vivo studies. Limitations arise from potential cardiac side effects that require attention. Further studies are warranted to provide a more complete understanding of hERG effects on apoptotic pathways. Downstream signaling proteins may serve as more specific therapeutic drug targets in future anticancer therapy.
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